Pfizer agrees to $190 mln settlement over generic Neurontin

NEW YORK, April 21 (Reuters) - Pfizer Inc has agreed to pay $190 million to settle a class-action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.